0001818382-24-000186.txt : 20240911 0001818382-24-000186.hdr.sgml : 20240911 20240911175312 ACCESSION NUMBER: 0001818382-24-000186 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240910 FILED AS OF DATE: 20240911 DATE AS OF CHANGE: 20240911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sebelius Kathleen CENTRAL INDEX KEY: 0001654316 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39532 FILM NUMBER: 241293440 MAIL ADDRESS: STREET 1: C/O DERMIRA, INC. STREET 2: 275 MIDDLEFIELD ROAD, SUITE 150 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Humacyte, Inc. CENTRAL INDEX KEY: 0001818382 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851763759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-313-9633 MAIL ADDRESS: STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200716 4 1 wk-form4_1726091586.xml FORM 4 X0508 4 2024-09-10 0 0001818382 Humacyte, Inc. HUMA 0001654316 Sebelius Kathleen 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 1 0 0 0 0 Common Stock 2024-09-10 4 M 0 4521 4.34 A 43910 D Common Stock 2024-09-10 4 S 0 3634 5.41 D 40276 D Common Stock 2024-09-10 4 M 0 2479 3.35 A 42755 D Common Stock 2024-09-10 4 S 0 1548 5.39 D 41207 D Stock Options (right to buy) 4.34 2024-09-10 4 M 0 4521 0 D 2024-08-09 2032-06-09 Common Stock 4521 3979 D Stock Options (right to buy) 3.35 2024-09-10 4 M 0 2479 0 D 2024-08-15 2033-06-15 Common Stock 2479 6021 D The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact 2024-09-11